secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001818382-23-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte nears enrollment completion in two pivotal HAV trials; cash to fund ops thru 2024
--------------------------------------------------------------------------------

- Phase 2/3 V005 trauma trial: 46 of 50 primary endpoint patients enrolled; BLA filing ~4 months after trial ends.
- Phase 3 V007 AV access trial: 238 of 240 patients enrolled; topline results one year after enrollment completion.
- Cash, equivalents & short-term investments: $151.9M at Dec 31, 2022, down from $225.5M; runway through end 2024.
- Q4 2022 net loss $3.7M vs net income $42.6M in Q4 2021; full-year net loss $12.0M vs $26.5M in 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/0001818382-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000014/huma-20230324.htm
  HTML page:      https://secwatch.observer/filing/0001818382-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer